The first immunosuppressant approved for the treatment of breast cancer, the PD-L1 inhibitor (Atezolizumab), was released in 2019, and it was approved by the FDA to be used in combination with Abraxane in patients with inoperable, locally advanced or metastatic triple-negative breast cancer 12. Here, CD274 is linked to breast carcinoma.